A new structural blueprint paves the way for improved targeting of cancer cells, particularly those with BRCA1 and BRCA2 ...

A new study by University of Arizona Health Sciences researchers found that an immunotherapy previously shown to be ineffective against prostate cancer may have therapeutic potential when combined ...

Antibody-drug conjugates (ADCs), which combine monoclonal antibodies with cytotoxic agents, offer a targeted approach to cancer therapy, aiming to deliver ...

Scientists have uncovered new genetic clues that explain why some prostate cancers remain slow-growing while others become life-threatening.

DNA repair proteins act like the body's editors, constantly finding and reversing damage to our genetic code. Researchers have long struggled to understand how cancer cells hijack one of these ...